Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 8, 2008 Brian Lawler	Novartis Sees More Growth Ahead Novartis makes one of the largest acquisitions in health-care history.
The Motley Fool April 22, 2008 Brian Lawler	No Earnings Holes for Novartis The drugmaker holds its own in Q1; all three of its major divisions experienced sales growth, even in the face of some tough comparisons to last year.
The Motley Fool January 29, 2009 Brian Orelli	Novartis: Diversification Isn't Good Enough Novartis has become a better diversified company, with acquisitions of vaccines specialist Chiron and 25% of eye-care specialist Alcon, but it's far from a cure all, as the fourth quarter showed.
The Motley Fool October 31, 2005 Rich Duprey	Chiron Not Immune to Merger The board accepts a sweetened buyout offer from Swiss pharmaceutical firm Novartis. Investors, take note.
The Motley Fool October 23, 2006 Brian Lawler	No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock.
BusinessWeek January 7, 2010 Capell & Doherty	What Novartis Sees in Eye Care Novartis CEO Dan Vasella's $50 billion bet on Alcon could help insulate it from the vagaries of the drug business.
The Motley Fool January 4, 2010 Brian Orelli	You Don't Need Your Contacts In to See This Deal Novartis acts first to grab the rest of Nestle's stake in Alcon.
The Motley Fool July 16, 2010 Brian Orelli	A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year.
The Motley Fool January 19, 2006 Stephen D. Simpson	Novartis Marches On While reported profits are masked by some charges, this Swiss drug company is still delivering the goods. Throw in a solid pipeline and a reasonable valuation, and the stock could still be worth a look for new money in the pharmaceutical space.
The Motley Fool October 23, 2009 Brian Orelli	Swine Flu Doesn't Need to Save Novartis The company is looking healthy all on its own.
The Motley Fool April 24, 2006 Stephen D. Simpson	Novartis: A Good Story Repeated Whether sales were a little light or not, this is still a high-quality pharmaceutical company. The company not only has a good pipeline, but the valuation is still attractive without needing to make particularly aggressive assumptions.
The Motley Fool January 20, 2010 Brian Orelli	Those Are Fighting Words Alcon's minority shareholders fight back.
The Motley Fool January 22, 2007 Brian Lawler	Another Busy Year in Store for Novartis Trying to place a value on Novartis is a tough thing to do now with so many important drugs awaiting regulatory review and its addiction to acquisitions and divestitures making financial comparisons between the years tough.
The Motley Fool September 21, 2005 Rich Duprey	A Shot of Reality for Chiron Novartis warns pharma it's willing to walk away from takeover bid. Does Chiron have the wherewithal to go it alone? Investors, take note.
The Motley Fool September 1, 2005 Stephen D. Simpson	Novartis Keeps Gorging Offering to buy the remainder of Chiron for $4.5 billion may up this company's execution risk over the next few quarters. Investors, take note.
The Motley Fool October 22, 2007 Brian Lawler	No Catastrophes at Novartis Novartis stays on track with its third-quarter results. Investors, take note.
The Motley Fool October 18, 2005 Stephen D. Simpson	More Good News From Novartis This Swiss drug giant continues to post steady growth. Investors, take note.
The Motley Fool July 14, 2005 Stephen D. Simpson	These Swiss Don't Miss Aside from a hiccup in margins, Novartis' drug business continues to shine. This pharma is a solid middle-of-the-road play with reasonable valuation, a solid pipeline, and a not-so-secret weapon in its Sandoz generics business.
The Motley Fool April 21, 2005 Stephen D. Simpson	Novartis' Triple Threat The Swiss drug giant boasts strong franchises in generics, cardiology, and oncology. It's hard not to think of Novartis as one of the highest-quality options in the pharmaceutical investing space.
The Motley Fool January 20, 2005 Stephen D. Simpson	Novartis Posts a Swiss Miss The Swiss drug giant has a strong pipeline, but moderate growth and high valuation suggest little room for error.
The Motley Fool September 24, 2010 Brian Orelli	So Long and Thanks for All the Drug Candidates Alnylam and Novartis end their five-year partnership.
The Motley Fool March 16, 2005 Cliff Malings	Nice of You to Notice Novartis The Street finally pays attention to a longtime pharma winner on news of a major generic-drug acquisition.
The Motley Fool July 16, 2009 Brian Orelli	A Strong Dollar Can Hurt Novartis makes it through a hard quarter.
The Motley Fool July 15, 2005 Stephen D. Simpson	Novartis' Over-the-Counter Tonic Novartis' latest purchase suggests a commitment to making itself a well-rounded pharma giant. Future margins may not be as high as they once were, but if the company can produce a lot more cash flow, investors won't mind a bit.
The Motley Fool July 7, 2010 Dave Mock	A Big Upgrade for Novartis This bullish call comes from more than just one analyst.
The Motley Fool June 29, 2009 Brian Orelli	Another Day, Another Rumored Suitor The rumors surrounding Elan's strategic review and its suitors just keep getting weirder.
The Motley Fool June 28, 2010 Brian Orelli	The Trouble Is They're Facing a Bazooka Alcon's minority shareholders are still fighting against Novartis' takeover.
The Motley Fool October 21, 2008 Brian Orelli	Novartis Is Taking the Road Less Traveled Diversification should pay off for this pharma giant.
The Motley Fool January 27, 2010 Brian Orelli	Nice, Novartis, Very Nice CEO Daniel Vasella leaves on a high note.
The Motley Fool October 27, 2009 Brian Orelli	Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions?
The Motley Fool September 7, 2005 Rich Duprey	Is Chiron Worth It? The vaccine maker rejects Novartis' bid of $40 a share as inadequate. How much should the pharma pay? Investors, take note.
The Motley Fool March 16, 2006 Rich Duprey	Chiron's Shareholder Revolt Hedge funds oppose the biotech's buyout by pharmaceutical giant Novartis. Investors, take note.
The Motley Fool July 17, 2006 Stephen D. Simpson	Novartis Pays for Its Shopping Spree Expenses from the Chiron acquisition bring down results for the second quarter. Investors, there's a lot to be said for waiting on the right price for even the best stocks out there.
The Motley Fool March 29, 2006 Stephen D. Simpson	Novartis Bulks Up Its Pipeline The Swiss drug giant once again pays up to add trial candidates to its portfolio. Investors, take note.
Inc. August 2008 Jim Melloan	Updates: Cashman Cashes In An update on Protez Pharmaceuticals, whose founder was seeking $500,000 in funding in 2005.
Chemistry World May 21, 2014 Phillip Broadwith	Novartis enhances its focus with eyecare deal Swiss pharma major Novartis is continuing its quest to excel in a few specialist fields by licensing rights to US firm Ophthotech's lead candidate, Fovista, for wet age-related macular degeneration.
The Motley Fool April 6, 2011 Brian Orelli	Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire.
The Motley Fool May 18, 2010 Brian Orelli	Price Inflation in Check? Not in This Industry. Drug prices are on the rise. For now.
The Motley Fool December 19, 2006 Brian Gorman	Novartis Cuts in Line at the Drugstore Consolidation in pharmacy benefits management may leave Novartis most resistant to pricing pressure. Investors, take note.
The Motley Fool February 22, 2005 Brian Gorman	Novartis Embraces Generics The company is taking a different path from its branded pharmaceutical peers. The company's strategy may make its stock worth a closer look.
The Motley Fool August 12, 2010 Brian Orelli	Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment.
The Motley Fool June 7, 2006 Stephen D. Simpson	Novartis Can't Say No The Swiss drug giant signs more deals to boost its pipeline. Investors, here is a strong company in a weak sector that's still somewhat undervalued -- not exactly the worst story of the week.
The Motley Fool April 4, 2006 Rich Duprey	Chiron's Booster Shot Novartis raises its bid for the biotech a second time, appeasing dissident shareholders.
The Motley Fool November 6, 2006 Brian Gorman	Novartis' China Gambit Novartis probably won't get any near-term dividend from its China investment, but the nation is too big to ignore. Investors, take note.
The Motley Fool April 25, 2007 Brian Lawler	Nothing Wrong With Novartis Novartis releases first-quarter financial results. Investors, take note.
Chemistry World January 24, 2014 Phillip Broadwith	Novartis and DSM trim jobs Pharmaceutical firm Novartis and nutritional products specialist DSM are both set to cut jobs in Switzerland.
The Motley Fool September 20, 2005 Brian Gorman	Novartis Stays Focused New developments at the drug giant suggest the company is on track. Investors, take note.
The Motley Fool July 17, 2007 Brian Lawler	Still Strong at Novartis For investors who are willing to filter the negative news and are patient enough to wait for recently launched branded compounds to help its top-line growth, Novartis is worth a look
The Motley Fool April 14, 2005 Brian Gorman	Novartis Moves on Multiple Fronts Even with its investment in a potential blockbuster, Novartis remains remarkably diversified. Investors can rest assured, though, that the company's strategy won't leave it as vulnerable as other outfits.
The Motley Fool May 21, 2009 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Pharma Goes Generic In the battle against generic rivals, it seems pharmaceutical companies would rather switch than fight. A pair of deals heralds Big Pharma's latest moves into the generic-drug world. See what Novartis and sanofi-aventis recently did.